Zelluna ASA Logo

Zelluna ASA

Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zelluna ASA is a clinical-stage biopharmaceutical company focused on developing treatments for solid cancers. The company is pioneering a proprietary, allogeneic T-cell receptor-based Natural Killer (TCR-NK) cell therapy platform. This "off-the-shelf" approach merges the targeting capabilities of T-cell receptors with the therapeutic functions of NK cells to address significant unmet medical needs in oncology. Zelluna's mission is to deliver transformative, safe, and cost-efficient therapies with the potential to cure patients with advanced solid tumors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 07:50
Board/Management Information
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financia…
English 4.2 KB
2025-11-27 08:35
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 1.8 KB
2025-11-25 16:05
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 1.4 KB
2025-11-25 12:09
Major Shareholding Notification
ZELLUNA ASA: DISCLOSURE OF LARGE SHAREHOLDING
English 1.5 KB
2025-11-25 11:32
Post-Annual General Meeting Information
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
English 325.0 KB
2025-11-25 11:32
Post-Annual General Meeting Information
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
Norwegian 258.2 KB
2025-11-25 11:32
Post-Annual General Meeting Information
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025
English 1.5 KB
2025-11-04 13:04
Pre-Annual General Meeting Information
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025 - Atta…
Norwegian 1014.6 KB
2025-11-04 13:04
Pre-Annual General Meeting Information
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025
English 1.4 KB
2025-11-04 09:10
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 986 bytes
2025-11-04 08:28
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 1.2 KB
2025-11-04 07:29
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 2.1 KB
2025-11-04 07:00
Share Issue/Capital Change
Zelluna ASA - Ex. date
English 550 bytes
2025-11-04 00:58
Share Issue/Capital Change
Zelluna ASA - Key information relating to subsequent offering
English 2.8 KB
2025-11-04 00:35
Share Issue/Capital Change
Zelluna ASA - Mandatory notification of trade - Attachment: 20251104 - PDMR att…
English 219.0 KB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Zelluna ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO

Talk to a Data Expert

Have a question? We'll get back to you promptly.